Clinical Evidence

Psilocybin Clinical Efficacy for Depression

(published  May 20211)

Phase II Trial: 24 patients with major depressive disorder, participants who received psilocybin-assisted therapy showed improvement in blinded clinician rated–assessed depression severity and in self-reported secondary outcomes through the one-month follow-up

Conclusion: Psilocybin was efficacious in producing large, rapid, and sustained antidepressant effects in patients with major depressive disorder

(published  November 20212)

Phase IIB Trial: Randomised, controlled 233 patients with treatment resistant depression (TRD) received single dose of psilocybin; showed reduction in symptoms of depression at three weeks through to completion (12 weeks) vs. controls.

Safety: 90% of adverse events were mild or moderate

Conclusion: Psilocybin showed statistical efficacy in benefiting patients with treatment resistant depression

  1. JAMA Psychiatry. 2021;78(5):481-489. doi:10.1001/jamapsychiatry.2020.3285

Psilocybin Headline Clinical Results

At Week 4

The benefit achieved with psilocybin treatment was approximately 4x greater than the effect with current depression treatments

Had a Clinically Significant Response to Psilocybin

Met the Criteria for Remission of Depression

  1. JAMA Psychiatry. 2021;78(5):481-489. doi:10.1001/jamapsychiatry.2020.3285

LSD Clinical Evidence

  • LSD, classical hallucinogen, used recreationally since 1938, banned in 1968 in the US and other countries
  • Considered to be non-addictive with low potential for abuse
  • Evaluated in numerous academic studies, showing behavioural changes, as well as remission of psychiatric symptoms1
  • LSD clinical studies showed therapeutic benefit maintained for >12 months after treatment
  • Target indications include anxiety, PTSD and substance abuse